If you want to know who really controls Pluristem Therapeutics Inc. (NASDAQ:PSTI), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

With a market capitalization of US$181m, Pluristem Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Pluristem Therapeutics.

View our latest analysis for Pluristem Therapeutics

What Does The Institutional Ownership Tell Us About Pluristem Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Pluristem Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Pluristem Therapeutics' earnings history below. Of course, the future is what really matters.

Hedge funds don't have many shares in Pluristem Therapeutics. Our data shows that Adi Wolf is the largest shareholder with 16% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 6.8% and 5.9%, of the shares outstanding, respectively. Zami Aberman, who is the third-largest shareholder, also happens to hold the title of Chairman of the Board. In addition, we found that Yaky Yanay, the CEO has 5.6% of the shares allocated to his name

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.